10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2018

CONSOLIDATED STATEMENTS OF EARNINGS

Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2018Dec 31, 2017Dec 31, 2016
Revenues
$
22,561
20,77619,427
Cost of Goods and Services Sold6,5476,0944,969
Marketing, selling and administrative4,5514,7514,979
Research and development6,3456,4825,012
Other income (net)(850)(1,682)(1,448)
Total Expenses16,59315,64513,512
 
Earnings Before Income Taxes5,9685,1315,915
 
Provision for Income Taxes1,0214,1561,408
Net Earnings4,9479754,507
 
Net Income (Loss) Attributable to Noncontrolling Interest27(32)50
Net Earnings Attributable to BMS4,9201,0074,457
 
Earnings per Common Share
Basic Earnings Per Common Share Attributable to BMS3.010.612.67
Diluted Earnings per Common Share Attributable to BMS3.010.612.65
Principal Transaction Revenue, Description of Reporting Category
Sales Revenue, Net
Revenues21,58119,25817,702
Alliance and other revenues
Revenues9801,5181,725
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2018

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2018Dec 31, 2017Dec 31, 2016
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]
Net Earnings
$
4,947
9754,507
Other Comprehensive Income (Loss), net of taxes and reclassifications to earnings [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax70(57)4
Pension and postretirement benefits53214(17)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax(25)3916
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax(254)18(38)
Other Comprehensive Income (Loss), Net of Tax(156)214(35)
 
Comprehensive Income4,7911,1894,472
 
Comprehensive Income Attributable to Noncontrolling Interest27(32)50
Comprehensive Income Attributable to BMS4,7641,2214,422
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2018

CONSOLIDATED STATEMENTS OF CASH FLOWS

Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2018Dec 31, 2017Dec 31, 2016
Cash Flows From Operating Activities:
Net Earnings
$
4,947
9754,507
Net Cash Provided by Operating Activities5,9405,2753,058
 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization, net637789382
Deferred income taxes861,010(204)
Stock-based compensation221199205
Impairment charges12632763
Pension settlements and amortization186236169
Divestiture gains and royalties(992)(706)(1,187)
Asset acquisition charges85760274
Loss/(gain) on equity investments512(23)37
Other adjustments(44)120(36)
Changes in operating assets and liabilities:
Receivables(429)(431)(803)
Inventories(216)(29)(152)
Accounts payable(59)320104
Deferred income84(642)(64)
Income taxes payable1622,597(453)
Other634(227)216
Cash Flows From Investing Activities:
Sale and maturities of marketable securities2,3796,4124,809
Purchase of marketable securities(2,305)(5,437)(3,089)
Capital expenditures(951)(1,055)(1,215)
Divestiture and other proceeds1,2497221,334
Acquisition and other payments(1,246)(708)(359)
Net Cash Provided by/(Used in) Investing Activities(874)(66)1,480
 
Cash Flows From Financing Activities:
Short-term borrowings, net(543)727125
Issuance of long-term debt01,4880
Repayment of long-term debt(5)(1,224)(15)
Repurchase of common stock(320)(2,469)(231)
Dividends(2,613)(2,577)(2,547)
Other(54)(22)15
Net Cash Used in Financing Activities(3,535)(4,077)(2,653)
 
Effect of Exchange Rates on Cash and Cash Equivalents(41)52(33)
Increase/(Decrease) in Cash and Cash Equivalents1,4901,1841,852
 
Cash and Cash Equivalents at Beginning of Year5,4214,237
Cash and Cash Equivalents at End of Year6,9115,4214,237
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

BRISTOL MYERS SQUIBB CO

Ticker: BMY   Fiscal Year: 2018

CONSOLIDATED BALANCE SHEETS

Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019)

(In Millions, except shares in actual)
 As ofAs of
 Dec 31, 2018Dec 31, 2017
ASSETS
Current Assets:
Cash and cash equivalents
$
6,911
5,421
Marketable securities, current1,9731,391
Receivables5,9656,300
Inventories1,1951,166
Prepaid expenses and other1,116576
Total Current Assets17,16014,854
 
Property, plant and equipment5,0275,001
Goodwill6,5386,863
Other intangible assets1,0911,210
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent1,3711,610
Marketable securities, noncurrent1,7752,480
Other Assets, Noncurrent2,0241,533
Total Assets34,98633,551
 
LIABILITIES
Current Liabilities:
Short-term debt obligations1,703987
Accounts payable1,8922,248
Accrued liabilities6,4896,014
Deferred income, current17283
Income taxes payable, current398231
Total Current Liabilities10,6549,563
 
Deferred income, noncurrent468454
Income taxes payable, noncurrent3,0433,548
Pension and other liabilities1,0481,164
Long-term debt, excluding current maturities5,6466,975
Total Liabilities20,85921,704
 
Commitments and contingencies  
EQUITY
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,070 in 2017 and 4,129 in 2016, liquidation value of $50 per share00
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2017 and 2016221221
Capital in excess of par value of stock2,0811,898
Accumulated other comprehensive loss(2,762)(2,289)
Retained earnings34,06531,160
Less cost of treasury stock - 575 million common shares in 2017 and 536 million in 2016(19,574)(19,249)
Total Bristol-Myers Squibb Company Shareholders' Equity14,03111,741
 
Noncontrolling interest96106
Total Equity14,12711,847
 
Total Liabilities and Equity34,98633,551
 
External Links 
BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2018
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip